Pure Global
NCT06330935

Evaluating the Effect of Tranexamic Acid on the Clinical Outcomes in Patients With Traumatic Brain Injury

Clinical Trial Evaluating the Effect of Tranexamic Acid on the Clinical Outcomes in Pediatric Patients With Traumatic Brain Injury
Mansoura University·Phase 1/2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Traumatic Brain Injury
Drug/Device/Intervention
Tranexamic Acid (TXA)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mansoura University
Location
Damietta, Egypt
Timeline & enrollment
Phase
Phase 1/2
Start date
Mar 25, 2024
End date
Mar 01, 2025
Enrollment
90 participants
Primary outcome

The early traumatic brain injury-related death in the hospital,The difference between treatment group in the Intracranial haemorrhage growth,The difference between the treatment groups in the incidence of mortality

Summary

Evaluate the effect of tranexamic acid on mortality in pediatric patients with traumatic
 brain injury. This could potentially lead to improved treatment protocols and better outcomes
 for this vulnerable population.

ICD-10 classifications
Diffuse brain injuryIntracranial injuryFocal brain injuryIntracranial injury, unspecifiedOther intracranial injuries
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06330935
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06330935 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Mansoura University and is currently Recruiting. The study focuses on Traumatic Brain Injury. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.